surmount-1 tirzepatide weight loss percent nejm 2022 Presented at ECO 2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body and waist circumference. Full trial Surmount Press Briefing #ADA2022

The XGBoost algorithm per se is not intended to be used in routine clinical work but was employed here to identify continuous baseline variables that predict the change in HbA1c and which can easily be evaluated by clinicians to provide a better overall assessment of the likely treatment response (such that for example a patient with high BMI or low insulin secretion will likely have a more pronounced response to a particular drug) in conjunction with other clinical data and the general patient context

While they contain the same medication, Wegovy comes in a structured, pre-filled pen or the new daily pill format

A patient or clinician can draw a fraction of a branded 2.5 mg tirzepatide vial, often starting around 0.5 mg, roughly a fifth of the lowest approved dose

6,7 As public awareness of GLP-1 therapy has increased, so has consumer interest in OTC products marketed as GLP-1 boosters

Yes, there are contraindications

Wegovy may be prescribed for weight loss, reducing the risk of cardiovascular disease, or treating advanced liver disease